The Board of Pharmacy has received notice of the following product recall:

Mesalamine Delayed-Release Tablets, USP 1.2 g

Lot #	Exp. Date	Strength	Bottle Size	NDC
1342500A	10/2020	1.2 g	120 Tablets	0591-2245-22

Teva Pharmaceuticals USA Inc. is recalling to the RETAIL LEVEL the above mentioned lot of **Mesalamine Delayed-Release Tablets, USP 1.2 g,** that was distributed under the **Actavis Pharma Inc.** label. This recall is being initiated due to an out of specification dissolution result observed during stability testing. The other analytical tests for the lot met specifications. Based on the health hazard assessment, use of the product being recalled may cause adverse health consequences such as reduced treatment efficacy, especially in patients experiencing flare-ups of the disease; nevertheless, the likelihood is remote by taking into consideration the close medical supervision of patients with ulcerative colitis.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.